FDA Clearance Tracker · P120016-S029
Vascade Vascular Closure System (VCS)
Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 1, 2023
Approved
Time to decision
180 days
Received Sep 2, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P120016-S029
- Device name
- Vascade Vascular Closure System (VCS)
- Applicant
- Cardiva Medical, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Sep 2, 2022
- Decided
- Mar 1, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P120016
Device type
- Device type
- Device, hemostasis, vascular (MGB)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the following changes:1) Increase in disc deployment diameter from 23F to 25F;2) Increase in collagen mass from 12 mg to 19 mg;3) Modifications to certain device components to accommodate the new disc deployment diameter and collagen mass; and4) Modifications to the Instructions for Use to reflect the changes in device design.
Source documents
Other decisions for Cardiva Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VASCADE MVP XL VVCS Model 800-1014XLPMA supplement
P120016-S039 · Decided Mar 27, 2026 · 178 days after receipt · Panel Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.